Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral respiratory tract infections are the most common cause of symptomatic human disease, accounting for more days lost from work than any other infection. Viral respiratory infections can present in myriad ways but most commonly present as two different clinical syndromes: the common cold or the flu. With the growing immunocompromised and elderly populations, viruses are now also recognized as major contributors to lower respiratory tract infections (LRTIs), including bronchitis, bronchiolitis, and, most importantly, viral pneumonia. In the past, viral pneumonia was classified as atypical pneumonia, a residual term from the beginning of the antibiotic era used for a pneumonia in which no bacterial pathogen could be identified and response to antibiotics was minimal.

Traditionally, the lack of focus on viral pneumonia resulted from limited antiviral treatment availability, poor diagnostic tests, and an impression that viral pathogens play a minor role in community-acquired pneumonia (CAP). Principally because of the development of nucleic acid amplification tests for diagnosis, viral pneumonia is now recognized as a major cause of CAP, causing anywhere from 18% to 28% of cases. CAP is a frequent and serious problem, contributing to significant morbidity and mortality in the United States. In patients on Medicare who are hospitalized with CAP, 1-year mortality may be as high as 40%. The fraction of those deaths that is actually from viral pneumonia is unclear.

PATHOGENESIS OF VIRAL PNEUMONIA

To cause pneumonia, the virus must reach the lower respiratory tract. Droplet transmission is often limited by distance. Airborne virus-containing droplets are initially deposited in the upper respiratory tract. Once the virus replicates and spreads within squamous epithelial cells, it eventually reaches the lower respiratory tract. Other viruses, including varicella and rubella, are transmitted through aerosols deposited directly to the lower respiratory tract. Direct contact is the least common pathway of transmission.

The interferon signaling system may be one of the most critical pathways in antiviral defense. The importance of Stat1, one activator of the transcription (JAK-STAT) pathway, has been verified with both human research and experimental models. For instance, Sendai virus, simian virus 5, and measles virus encode for V and C proteins that inhibit Stat1 expression and activation. Furthermore, respiratory syncytial virus (RSV) has developed three different mechanisms to block interferon signaling. Viruses may also be able to manipulate the relationship between the airway epithelial cells and lung macrophages. For example, RSV infection may provide an antia apoptotic signal to macrophages, which leaves viral replication and subsequent inflammation unchecked. This chain of events can potentially lead to lethal outcome from an otherwise controllable infection.
Viral infection of the lower respiratory tract can produce severe disease through triggering an inflammatory and cytokine response sufficient to cause acute lung injury, eventually developing into diffuse alveolar damage or acute respiratory distress syndrome (ARDS). Mouse models suggest that the lethal effect of viral pneumonia is more likely secondary to the host response than to a direct cytopathic result of viral replication.9 Although not as common, viral invasion and replication can directly cause a necrotizing bronchopneumonia with inflammatory and exudative reactions.

**Immunosuppression and Viral Infections**

In the past few decades, the number of patients who are immunosuppressed has increased dramatically. This growth is largely secondary to the global epidemic of HIV, the development of more aggressive and successful chemotherapy regimens, and the progress of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT).10 Despite advances in treating infections and significant progress with new preventative techniques,11 infection continues to be the leading cause of death in these populations. Patients who are immunocompromised have long been recognized as higher risk for viral pneumonia, including herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus, and measles. Over the past few decades, RSV, influenza, parainfluenza (PIV), adenovirus, picornavirus, and human metapneumovirus (hMPV) have also been recognized as causes of pneumonia in the immunocompromised population. In a study of viral infections in patient who had undergone HSCT, the incidence of influenza ranged from 14% to 52%, RSV from 14% to 48%, adenovirus from 2% to 21%, and PIV from 11% to 49% of all viral isolates.12 The incidence and outcome of these viral pneumonias can vary significantly based on the intensity and duration of T-cell–mediated immune suppression.11,13 Other factors in the pathogenesis of viral infections include stem cell product, donor–recipient matching and appropriate screening in both, composition of the conditioning regimen, and graft-versus-host disease.

**Bacterial Superinfection**

Although influenza and other viral pneumonias can themselves be fatal, a substantial number of viral pneumonia deaths result from secondary bacterial pneumonia.7,14 The most common culprit is *Streptococcus pneumoniae*, followed by *Staphylococcus aureus* and *Hemophilus influenzae*.14,15 This lethal combination may be partially from the viral effects on the host, such as epithelial damage within the respiratory tract and changes in airway function. Influenza A infection, the most commonly studied virus in this area of research, can also alter the inflammatory and immune response. Both influenza and bacterial infections use similar pathways, cofactors, and intermediates, and the overlap in the inflammatory mediators produced may create an interference with or augmentation of the host immune response.16 This alteration of the immune response contributes to the severity of the resulting infection either through diminishing the ability of the host to clear the bacteria or through amplification of the inflammatory cascade. The overwhelming inflammatory cascade is usually the culprit in rapidly progressive lower respiratory tract disease resulting in ARDS.17,18

**CLINICAL MANIFESTATIONS**

The presentation of viral pneumonia varies widely. Unfortunately, no clinical predictors reliably distinguish between viral and bacterial pneumonia.4 Many patients with viral pneumonia present with dyspnea, cough, sputum production, and pleuritic chest pain. Other patients, especially those who are over age of 65 years old, lack any of the above symptoms and instead present with altered mental status or falls. In studies of patients who are elderly and frail, those with viral pneumonia more often present with cardiac disease, lower white blood cell and neutrophil counts, and less frequent chest pain and rigors.19

**RADIOLOGIC FINDINGS**

Viral pneumonia has a variety of radiographic presentations. Again, no findings reliably predict a specific pathogen or differentiate between viral and bacterial pneumonia. Despite this, two different pathologic processes are reflected in two common radiographic patterns: a slowly progressive, insidious course of pneumonia and a rapidly progressive or virulent pneumonia.20 The insidious form is characterized by lymphatic infiltrates in the alveolar septa, which may extend to the areas adjacent to the terminal and respiratory bronchioles. On CT scan, well-defined nodules and patchy areas of peribronchial ground-glass opacity and air-space consolidation are seen. Because the viruses are intracellular, most of the pathologic changes tend to occur in the epithelium and adjacent interstitial tissue. In the rapidly progressive form, the underlying disease process
is often diffuse alveolar hemorrhage and the infiltrate often extends to the interstitium and alveolar space. The chest radiograph often shows a rapid presentation of patchy unilateral or bilateral consolidations and ground-glass opacities. Poorly defined centrilobular nodules may also be present.

**SPECIFIC VIRUSES**

**Influenza**

**Pathogenesis**

Influenza viruses are the only paramyxoviruses capable of causing disease in humans. Influenza A, the most virulent subtype, possesses eight negative-sense RNA segments that encode 11 known proteins. Of these proteins, two large viral surface glycoproteins on the outside of the viral particles, hemagglutinin (HA) and neuraminidase (NA), form the basis of multiple serologically distinct subtypes. To initiate infection, HA binds to sialic acid residues on the respiratory epithelial cell surface glycoproteins. Protease-mediated cleavage of HA results in its endocytosis, where the low pH of the endosome promotes uncoating of the virion and viral replication, eventually leading to the death of the epithelial cell. Once viral replication occurs, progeny virions are bound to the host cell. NA cleaves the links between the virions and host cell. Recently, 16 HA and 9 NA subtypes have been identified in wild water birds, the natural host for all influenza A viruses.

**Epidemiology**

Influenza viruses have distinct outbreaks every year. Although both influenza A and influenza B cause infection, influenza A virus has a remarkable ability to undergo periodic changes in the antigenic characteristics of NA and HA. Influenza A viruses that infect humans are from three major subtypes of HA (H1, H2, H3) and two subtypes of NA (N1 and N2). When NA or HA undergo stepwise point mutations in the RNA gene segments as the virus replicates, antigenic drift occurs. When two different viruses coinfect a single host, this host can act as a “mixing vessel” and a new virus is created by reassortment of the genomic segments. Major changes such as these antigenic shifts can cause epidemics and pandemics.

Although infection can occur all year round in tropical regions, outbreaks of influenza in the northern and southern hemisphere are almost exclusively in the winter months. People at higher risk for influenza include those with known pulmonary or cardiovascular disease, diabetes, or renal disease; immunosuppressed individuals; nursing home or chronic care facility residents; or healthy individuals older than 50 years.

**Recent H1N1 outbreak**

In late March 2009, an outbreak of a novel H1N1 influenza A virus was detected in Mexico. This outbreak represented a rare quadruple reassortment of two swine strains, one human strain, and one avian strain of influenza. As a result of airline travel, the pandemic spread rapidly. Using a modeling study, the Centers for Disease Control and Prevention (CDC) estimated 61 million cases, 274,000 hospitalizations, and 12,470 deaths occurred in the United States from April 2009 to April 2010. Even though deaths during the pandemic were fewer than the number of influenza deaths during nonpandemic years, mortality disproportionately affected younger individuals. A similar outbreak in 1957 may have provided preexisting immunity to protect the elderly people. Of those hospitalized, 70% had a known underlying high-risk condition, including chronic lung disease (37%), immunosuppressive conditions (17%), pregnancy (17%), cardiac disease (17%), obesity (13%), and diabetes (13%). Asthma was also prevalent among children and adults who were hospitalized.

The 2009 novel H1N1 pandemic gave several important insights into influenza pneumonia. Previously, antiviral therapy was only recommended for patients with a recent onset of symptoms. Because most studies showed a significant survival benefit for early antiviral treatment, antivirals were also recommended for those with suspected or confirmed H1N1 influenza A infection who were severely ill or had risk factors for a complicated course. The U.S. Food and Drug Administration (FDA) authorized emergency use of a new intravenous neuraminidase inhibitor, peramivir, for patients unable to take inhaled or oral neuraminidase inhibitors, and possibly for those who experienced no response to other neuraminidase inhibitors. Now that the outbreak has ended, peramivir is no longer approved for use in patients with influenza. Because of the H1N1 epidemic, vaccination is now recommended for all individuals older than 6 months.

Corticosteroids were also studied during the recent pandemic. Two of the most recently published studies showed that corticosteroids were associated with higher mortality, especially when given early. These patients tended to have longer duration of mechanical ventilation in addition to higher incidences of acquired pneumonia, including both secondary bacterial pneumonia and invasive fungal infection. These findings are consistent with the results of steroid treatment in severe acute respiratory syndrome (SARS) and avian influenza, suggesting that steroid treatment...
of acute lung injury caused by viral pneumonia may be contraindicated.

Clinical findings
After an incubation period of 1 or 2 days, influenza usually presents acutely with fever, headache, malaise, and myalgias along with cough and sore throat. Pneumonia is the most common complication of influenza, but other complications include central nervous involvement, myocarditis, myositis, and rhabdomyolysis. Primary influenza pneumonia presents with dyspnea, persistent high fever, and significant hypoxia. Secondary bacterial pneumonia is a common complication of influenza and is responsible for 25% of all influenza deaths. These patients usually present with recurrence of fever and new respiratory symptoms after the initial viral syndrome has begun to abate. Increasingly, concomitant influenza and bacterial pneumonia is being recognized, with a significantly higher mortality, especially with S. aureus. S. aureus can express cytotoxins, such as Panton-Valentin leukocidin, that have the ability to cause severe necrotizing pneumonia both directly through direct toxic activity and indirectly through the upregulation of surface proteins. The mortality associated from the Panton-Valentin leukocidin–associated staphylococcal infection ranges from 56% to 61%. Myositis and rhabdomyolysis often present with significant tenderness of the muscles along with elevated creatine phosphokinase levels, myoglobinuria, and renal failure. Central nervous involvement may include transverse myelitis, Guillain-Barré syndrome, aseptic meningitis, and encephalitis.

Diagnosis
In many circumstances, influenza can be diagnosed clinically, and diagnostic testing is unnecessary. Reverse transcriptase-polymerase chain reaction (RT-PCR) is the preferred method of diagnosis. RT-PCR can also distinguish between different subtypes of influenza infection, which is important when different strains with different antiviral resistance patterns are both circulating. RT-PCR only takes 4 to 6 hours to run but may be delayed if not performed in-house. Although rapid antigen and immunofluorescence assays are useful if positive, the limited sensitivity of presently available tests does not warrant their use. Cultures are less sensitive and clearly delayed compared with RT-PCR.

Prevention
Vaccination is a major method of disease control during influenza season. The CDC regularly tracks influenza viral isolates throughout the world to monitor disease activity and predict components for the annual influenza vaccine that best match the circulating viruses for the next season. As seen in the recent H1N1 pandemic, vaccine strains are chosen according to previous viral strains. Consequently, anticipating pandemics or epidemics created by large antigenic shifts can be difficult.

In 2010, new recommendations from the Advisory Committee on Immunization Practices (ACIP) included vaccination for all individuals older than 6 months, expanding the previous recommendation of only individuals at high risk for influenza complications and people in close contact with those individuals.

The influenza vaccines licensed for use in the United States are the intramuscular trivalent inactivated influenza vaccine and an intranasal trivalent live, attenuated, cold-adapted influenza vaccine. The inactivated vaccine includes inactivated preparations of the whole virus or subvirion components (also called the “split product”). Only split product vaccines are available in the United States and are preferred for use of children younger than 12 years. The live, attenuated intranasal vaccine should not be administered to patients who are immunosuppressed or pregnant; have a history of Guillain-Barré syndrome; or have cardiovascular, pulmonary, or metabolic disease; or to household members or health care professionals in close contact with patients who are immunocompromised. Neither vaccine should be given to individuals with history of anaphylaxis caused by eggs or other components of vaccine.

In general, vaccine and placebo recipients report similar rates of fever, myalgias, fatigue, malaise, and headaches. Concern over an association between Guillain-Barré syndrome and influenza vaccine was highlighted with the A/New Jersey (swine) influenza vaccine administered in 1976. Subsequent studies show a significant decline in the association between influenza inoculation and Guillain-Barré syndrome.

Treatment
All patients with severe disease or high-risk status (Box 1) should be treated with antiviral therapy. People with severe disease include those with evidence of LRTI or who are hospitalized. Adults younger than 65 years without chronic medical conditions and only mild illness do not require testing, but treatment within 48 hours of their illness onset may reduce duration of symptoms.

Adamantanes
The adamantanes, amantadine and rimantadine, prevent viral replication through blocking the viral
M2 protein ion channel, preventing fusion of virus and host cell membranes.\textsuperscript{50} The ACIP recommended against the routine use of adamantanes for influenza infection in 2008.\textsuperscript{48} Amantadines are now recommended only for patients at risk of oseltamivir-resistant influenza and who have a contraindication to zanamivir therapy. Although side effects are not common for rimantadine, amantadine has significant central nervous system side effects (eg, nervousness, anxiety, insomnia, difficulty concentrating, lightheadedness).\textsuperscript{51}

**Neuraminidase inhibitors**

The neuraminidase inhibitors, zanamivir and oseltamivir, selectively inhibit the neuraminidase of both influenza A and B viruses.\textsuperscript{21} Neuraminidase inhibitors block the active sites of NA and leave uncleaved sialic acid residues on the surfaces of host cells and influenza viral envelopes. As a result, viral HA binding to the uncleaved sialic acid residues leads to viral aggregation at the host cell surface and a reduced release of virus.\textsuperscript{52}

When administered within 24 to 48 hours, antivirals can reduce the duration of symptoms from 1 to 3 days.\textsuperscript{53,54} In addition to shortening the duration of symptoms, early initiation of oseltamivir decreases overall mortality\textsuperscript{32,55} and length of hospitalization in cases of severe influenza.\textsuperscript{56} Zanamivir is available for oral inhalation, but intravenous administration is still being evaluated in clinical trials.\textsuperscript{57} Because zanamivir induced bronchospasm and decreased lung function in some patients, it is contraindicated in patients with underlying asthma or other chronic respiratory conditions. Before 2007, resistance to oseltamivir occurred in 1% to 5% of patients.\textsuperscript{58,59} Since 2007, several different outbreaks of oseltamivir-resistant influenza have occurred.\textsuperscript{60,61} Patients who are immunocompromised seem to have a higher incidence of resistance, which is thought to result from prolonged viral shedding.\textsuperscript{62}

**PIV**

PIVs are important respiratory viral pathogens with presentations ranging from mild upper respiratory tract infections in adults who are immunocompetent to life-threatening LRTIs in those who are immunocompromised. PIV-3, representing 52% of all PIV infections, and is endemic year-round.\textsuperscript{53} PIV-1 and PIV-2 (representing 26% and 12% of all the PIV infections) tend to peak during the fall months. Although pneumonia is rare, infection usually recurs throughout adulthood and accounts for 1% to 15% of acute febrile respiratory illnesses. In a prospective study of the role of viruses in CAP since the advent of nucleic amplification tests, 3 of 75 (4%) of patients who had a pathogen identified were found to have PIV.\textsuperscript{19} Despite the low incidence of pneumonia in the general adult population, PIV pneumonia commonly afflicts elderly people, especially nursing home residents.\textsuperscript{64}

Among patients who are immunocompromised, PIV infection is known to cause significant morbidity and mortality.\textsuperscript{65} For example, in a study of more than 1000 patients who underwent bone marrow transplants, although only 5.2% tested positive for PIV, 44% of these developed pneumonia, with a mortality of 37% (10 of 27 patients).\textsuperscript{66} Glucocorticoids were associated with an increased risk of progression from upper to lower tract disease and mortality in patients who had undergone HSCT.\textsuperscript{67} Lung transplant recipients are also prone to PIV infection, with an estimated incidence of 5.3 per every 100 patients,\textsuperscript{68} with LRTIs in 10% to 66% of cases. Patients who have undergone lung transplants and acquire PIV have worse short- and long-term pulmonary dysfunction, along with more acute rejection episodes\textsuperscript{68} and bronchiolitis obliterans.\textsuperscript{69}

Because most of these studies involve inpatients, the incidence of PIV infection may be underestimated and severity may therefore be overestimated. However, outbreaks have been discovered among HSCT units, and asymptomatic shedding of HSCT recipients is common.\textsuperscript{70,71} Therefore, nosocomial acquisition is a major concern.

Polymerase chain reaction (PCR), specifically multiplex PCR, is now the preferred method of testing, especially in the immunocompromised population. Compared with culture, RT-PCR enzyme hybridization assay shows 100% sensitivity (95% CI, 0.66–1.00) and 95% specificity (95% CI, 0.88–0.99).\textsuperscript{72–74}

No treatment has proven efficacy for PIV infection. In patients who are immunosuppressed, the most common treatment is reduction of...
immunosuppression. Aerosolized ribavirin with or without intravenous immunoglobulin in HSCT recipients did not change mortality or viral shedding from the nasopharynx with either treatment group. An inhibitor of HA and NA and a recombinant sialidase fusion protein with potent in vitro and in vivo activity against PIV are being studied.

**RSV**

**Epidemiology**

Although widely known to be the leading cause of LRTI among infants and children, RSV also causes significant LRTI among older children and adults, especially people who are elderly and immunocompromised. Although mortality from RSV in children has declined, the number of hospitalizations climbs yearly; recent estimates are approximately 120,000 hospitalizations each year. RSV infections are responsible for approximately 2700 deaths in adults and children every year.

Direct contact is the most common form of transmission, but RSV can also be transmitted through large aerosol droplets. In temperate climates, RSV typically peaks in winter months, whereas in tropical and semitropical climates, the outbreaks usually occur throughout the rainy season. Patients at risk for more severe infections include infants, children with comorbid conditions, institutionalized adults, and people who are immunosuppressed.

**Clinical findings**

The clinical presentation of RSV infection varies significantly. Typically, younger children and infants with RSV infection develop LRTI symptoms, including pneumonia, bronchiolitis, or severe respiratory failure. Although LRTI is common with an individual's first RSV infection, it decreases with subsequent infections. RSV infection can also alter the sensitivity of the laryngeal chemoreceptors and cause apnea in infants. Almost 20% of infants who present with apnea are found to have RSV infection. Upper respiratory tract infections are also common in children and adults, with wheezing the most common presenting symptom. Adults who are immunocompetent rarely develop pneumonia with RSV infection. Patients who are immunocompromised often present with pneumonia that may progress to respiratory failure. Although RSV infection can cause substantial mortality in patients who have undergone a bone marrow transplant, no long-term sequelae to RSV infection are found and pulmonary function returns to normal.

**Radiographic findings**

In children, the radiographic appearance of RSV infection also varies. Controlling for several factors, including bacterial superinfection and age of child, the most common findings on chest radiograph are normal (30%), central pneumonia (32%), or peribronchitis (26%). Less common findings are emphysema (11%), pleural effusion (6%), lobar- or broncho-pneumonia (each 6%), atelectasis (5%), or pneumothorax. In immunocompromised patients, radiographic findings vary from ground-glass attenuation to tree-in-bud opacities to consolidation.

**Diagnosis**

In mild cases of RSV infection, the diagnosis can be made clinically. If hospitalization and treatment are necessary, diagnosis should be confirmed. In children, nasopharyngeal wash is preferred, although nasopharyngeal swab or throat culture is often adequate. In patients who are intubated or immunocompromised, bronchoalveolar lavage provides the highest diagnostic yield. Because the definitive diagnosis through isolation of the virus in HEp-2 cells can take weeks, multiplex PCR assay is preferred, especially in the immunocompromised population.

**Treatment**

The primary management of significant RSV infection is supportive care. If lower airway obstruction is present, a trial of β-agonist or aerosolized racemic epinephrine is recommended but should not be continued if no significant clinical improvement results. Although racemic epinephrine did not shorten hospital stay nor improve other comorbid conditions associated with bronchiolitis after hospital discharge, the medication improved respiratory distress. Despite the potential benefit of decreased bronchiolar swelling and airway obstruction, corticosteroids have not been shown to benefit patients with bronchiolitis and are not recommended for infants with RSV bronchiolitis or pneumonia. If RSV causes an asthma exacerbation in older children or adults, corticosteroid treatment is reasonable.

The FDA has approved ribavirin, a synthetic nucleoside analog administered through continuous aerosol, for the treatment of RSV infection. Although FDA-approved, routine use of nebulized ribavirin in infants and children with RSV is not recommended by the American Academy of Pediatrics (AAP). A beneficial effect of this therapy has not been proven and several studies show conflicting results. Concerns for toxicity limit use, and ribavirin should never be administered to pregnant patients, and supportive staff working...
with the patient should not be pregnant. Intravenous immunoglobulin with high neutralizing activity against RSV or monoclonal antibody for infants or young children has no proven benefit with RSV infection. Ribavirin and immunotherapy also have shown no substantial benefit in patients who are immunocompromised and severely ill with RSV infection. Ribavirin and immunotherapy may have the greatest potential benefit in preventing the progression of upper respiratory tract infection to LRTI.

**Prevention**

Intravenous immunoglobulin has been shown to be safe and effective in decreasing the severity of RSV infections. The AAP now recommends that palivizumab, a humanized monoclonal antibody against the RSV F glycoprotein, be considered for infants and children at risk for severe RSV infection, including those with bronchopulmonary dysplasia, prematurity, and hemodynamically significant congenital heart disease. Multiple factors have limited the development of more effective live, attenuated RSV vaccines, including potentiation of disease in people who have been vaccinated and subsequently become infected with wild-type virus.

**Adenovirus**

**Epidemiology**

Adenovirus is the most common cause of pharyngitis and coryza in young children, and causes 5% to 10% of all febrile illnesses in infants and young children. Of all young children who contract adenovirus, 10% will develop pneumonia, most commonly with serotype 14. Although most infections are self-limiting and mild, adenovirus also causes potentially fatal pneumonia in patients who are immunocompromised. In a study of more than 200 of bone marrow transplant recipients, 20.9% had evidence of adenovirus infection and 6.2% developed invasive disease. The high incidence of adenovirus infection in this particular study may be secondary to more intensive immunosuppressive regimens. Nonpneumonic disease, such as colitis, hepatitis, hemorrhagic cystitis, tubulointerstitial nephritis, encephalitis, or disseminated disease, can also be seen in patients who have undergone HSCT. For patients who have undergone solid organ transplants, the most common presenting symptom for adenovirus infection is strongly associated with the transplanted organ (eg, liver transplant recipients present with hepatitis, lung transplant recipients with pneumonia).

In the early 1950s to 1960s, almost 10% of all military recruits were infected with adenovirus, representing 90% of the pneumonia hospitalizations in that population. As a result, all military recruits received oral, live enteric-coated vaccines starting in 1971. In 1996, the manufacturer of the vaccine ceased production and outbreaks of adenoviral respiratory illness reemerged, with approximately 10% of all recruits again ill with adenovirus infection. Efforts to contain the virus have not been successful. Therefore, interest in vaccination has again increased. A double-blind placebo-controlled study of new live, oral, type 4 and type 7 adenovirus vaccines in adult military recruits found the vaccines to be safe and to induce an appropriate immune response. Further trials are in progress.

Once again, PCR has become the diagnostic method of choice, replacing viral culture of a nasopharyngeal aspirate or swab, throat swab, or sputum. Since adenoviral infection is usually self-limited, treatment is mostly supportive. Antiviral treatments are usually reserved for immunocompromised patients and those individuals with severe disease. Cidofovir, an acyclic nucleoside phosphonate with broad-spectrum activity against a wide variety of DNA viruses, has been tried. Small studies have shown mixed results particularly with adenoviral pneumonia. Combination with pooled intravenous immunoglobulin (IVIg) may be more effective. Mortality was only 19% in patients who are severely immunocompromised with adenovirus infection treated with cidofovir and IVIg, compared with the historical control mortality of 26% overall, with 73% mortality in patients with pneumonia.

**Rhinovirus**

Rhinovirus is responsible for 30% of all upper respiratory tract infections, including a third to half of all colds in adults. Rhinovirus is responsible for one to three respiratory illnesses per year in adults and four to eight per year in healthy children. Although most often self-limited, rhinovirus can cause LRTIs, particularly in patients who are immunocompromised, and can trigger asthma exacerbations. Although aerosol transmission is possible, the most common mode of transmission is self-inoculation through the nose or conjunctival surfaces.

Rhinovirus usually presents as the common cold, including cough, nasal discharge, and nasal obstruction. In contrast to adults, children may have fever early in the illness. Symptoms in adults usually resolve within a week, whereas children often continue to report symptoms for at least 7 to 10 days. Rhinovirus may significantly contribute to asthma exacerbations and wheezing in...
both children and young adults. The virus is responsible for 15% of pneumonias within the first month of life and is also very common in patients who are immunosuppressed. Mortality as high as 32% has been reported in bone marrow transplant recipients.

In most cases, diagnosis is not necessary and patients are given supportive care. If diagnosis is necessary, PCR is the gold standard. Viral culture is time-consuming and has poor sensitivity and specificity. Because of the multiplicity of serotypes, rapid antigen detection and serologic tests do not exist for rhinovirus infections.

Treatment
Rhinovirus is usually self-limited and the mainstay of therapy usually includes rest, hydration, and nasal decongestants. In a double-blind, randomized, placebo-controlled trial of oral pleconaril for treatment of colds caused by picornaviruses in adults, median time to alleviation of symptoms was found to be 1 day shorter compared with placebo. Prednisolone was also found to be promising for the treatment of rhinovirus infection. During a 2-month period after the first episodes of wheezing, prednisolone was found to reduce rhinovirus relapses. A randomized double-blind study of a recombinant soluble intercellular adhesion molecule-1 (ICAM-1) administered intranasally sex times per day, beginning either 7 hours before or 12 hours after rhinovirus challenge, showed no effect on the incidence of infection, although clinical colds, total symptoms score, and nasal secretion weight decreased. A virally encoded enzyme, 3C protease, which cleaves viral proteins from precursor polyproteins essential for the viral replication and virion assembly, is currently in phase II trials. Although some of these treatments show promise, more studies must be completed, and standard treatment for rhinovirus remains supportive care.

hMPV
Although in retrospect hMPV has caused infection for the past 50 years, it was only recently discovered after successful isolation from symptomatic children in the Netherlands. Because hMPV is only newly recognized, detailed data are limited. Although hMPV can cause upper respiratory tract infection and LRTIs in all age groups, symptomatic infection is most common in young children and older adults. In individuals with LRTIs, bronchiolitis (59%), croup (18%), asthma exacerbation (14%), and pneumonia (8%) are the most common presentations. For adults, the most common presentations include cough (100%), nasal congestion (85%), rhinorrhea (75%), dyspnea (69%), hoarseness (67%), and wheezing (62%). Despite usually being self-limiting, hMPV infection may account for the hospitalization of a significant portion of persons with respiratory infections.

Similar to the other viral infections, hMPV has more severe consequences in the immunocompromised population. In a prospective study of 251 patients with hematologic malignancies presenting with upper respiratory tract infections and LRTIs, 9% of the infections were associated with hMPV. Of these, 16 of 22 occurred in patients who underwent HSCT. Only 9 of 251 (3.6%) had hMPV pneumonia but 3 died. Another retrospective study of HSCT patients found hMPV in the bronchoalveolar lavage of 5 of 163 patients (3%) and 4 of 5 patients died from overwhelming respiratory failure and shock. This study emphasized the importance of waiting for mild upper respiratory tract infections to clear before transplantation.

hMPV can be isolated from viral culture but grows slowly and inefficiently. RT-PCR is the most sensitive method for diagnosing hMPV infection. Serology is another method of detection. Although clinical colds, total symptoms score, and nasal secretion weight decreased. A virally encoded enzyme, 3C protease, which cleaves viral proteins from precursor polyproteins essential for the viral replication and virion assembly, is currently in phase II trials. Although some of these treatments show promise, more studies must be completed, and standard treatment for rhinovirus remains supportive care.

SARS Coronavirus
Epidemiology
The SARS coronavirus was discovered during the near-pandemic that infected 8096 individuals with 774 confirmed deaths between November 2002 and July 2003. SARS is a highly contagious, severe, atypical pneumonia first noted in Guangdong Province in Southern China. The index case for the epidemic was a physician who traveled to Hong Kong 5 days after the onset of his symptoms. The virus spread rapidly from southern China and Hong Kong to Vietnam, Thailand, and Singapore, eventually spreading to Europe, Canada, and the United States. The virus was not identified as a new viral strain from the SARS epidemic case-fatality rate was 9.6%. After extraordinary efforts at containment, no new cases were identified after July 2003. Most of the patients were adults; health care workers accounted for nearly 23% of these cases, testifying to the high infectivity. Since then, smaller outbreaks have occurred because of laboratory transmission and contact with animal sources.

This SARS epidemic case-fatality rate was 9.6%. Mortality was strongly associated with age: the estimated case fatality rate was 13.2% for patients younger than 60 years and 43.3% for...
patients aged 60 years or older. Younger children (<12 years) had milder disease with no mortality.

Because of the rapid and extensive spread of SARS, multiple modes of transmission, including droplet, airborne, and close contact, were suspected. Environmental sampling showed that both air samples and swab samples from surfaces of a room containing a patient with SARS were PCR-positive. Even the medication refrigerator door in the nursing station was PCR-positive. These findings stressed the need for adequate respiratory protection along with strict surface hygiene practices.

**Clinical presentation**
SARS is a respiratory viral disease with an atypical prolonged prodrome, most commonly presenting with fever, cough, chills, rigors, myalgias, dyspnea, and headache. As the disease progresses, respiratory symptoms become more severe, often necessitating admission to the intensive care unit (ICU) and mechanical ventilation (approximately 26% of patients). Death is most commonly attributable to ARDS and multiorgan failure. Laboratory findings include lymphopenia, thrombocytopenia, elevated alanine aminotransferase, elevated C-reactive protein, and elevated lactate dehydrogenase. Elevated lactate dehydrogenase is associated with poor outcome. Although chest radiographs often vary in appearance, the most common presentation is focal peripheral air-space disease with gradual resolution. Even when initial chest radiographs are normal, CT scan usually shows parenchymal abnormalities.

**Diagnosis**
Because of both limited sensitivity and specificity, positive RT-PCR from two separate samples (either two different sites or the same site on two different occasions) is recommended for diagnosis. The alternative is culture of the virus from any clinical specimen or detection of antibody by enzyme-linked immunosorbent assay or immunofluorescent assay. When SARS is suspected, initially negative RT-PCR should be repeated, because the sensitivity can be poor in the early stages of disease. Although serologic testing is the most sensitive test available, several weeks are required before antibodies develop: the mean time to seroconversion is 19 to 20 days. Because these tests can cross-react with other human coronaviruses, false-positive results are also seen.

**Treatment**
Although several different treatments were tried during the recent epidemic, none were proven to have beneficial effect, including high-dose glucocorticoids and ribavirin. Since the outbreak, lopinavir-ritonavir, interferon-α, and convalescent plasma have been tried in a smaller number of patients or in animal models without proven clinical efficacy. Aggressive infection control standards were the key to control of the most recent epidemic. Vaccination and monoclonal antibodies are currently not ready for human subjects. Concern that subsequent exposure to the SARS coronavirus after vaccination could lead to paradoxically severe disease may limit vaccination trials.

**Varicella Pneumonia**

**Epidemiology**
Varicella pneumonia is a rare complication in immunocompetent children. In adults, the reported incidence of varicella pneumonia is approximately 1 in every 400 cases. Although the incidence of varicella pneumonia has decreased significantly since the introduction of the vaccine, most morbidity and mortality seen from varicella infection in adults are from pneumonia. The decrease in adult pneumonia is likely secondary to herd immunity from child immunization rather than adult immunization. Despite the lower incidence, mortality from varicella pneumonia in immunocompetent individuals is staggering (up to 25%). Risk factors for the development of varicella pneumonia include cigarette smoking, immunocompromised state, and pregnancy. Overall, the severity of varicella pneumonia is highest in immunosuppressed individuals (mortality, 15%–18%) and in pregnant women in the second and third trimesters (mortality, 41%). Although only 0.1% of varicella infections develop in patients who are immunosuppressed, they accounted for approximately 25% of varicella-related deaths before the development of the vaccine. The incidence and complication rates have decreased because of early initiation of acyclovir for high-risk individuals and vaccination of those in close contact with people who are immunosuppressed and were not candidates for varicella vaccination.

**Pathogenesis**
VZV is a human herpesvirus that infects nearly all humans and causes chickenpox (varicella). Once a patient contracts chickenpox, VZV becomes latent in cranial nerve, dorsal root, and autonomic nervous system ganglia. Reactivation of the virus can produce shingles (herpes zoster), which is characterized by pain and rash.
Clinical presentation
The varicella rash usually starts with fever along with a pruritic, vesicular rash commonly involving the mucosa. Typically, varicella pneumonia develops 1 to 6 days after the appearance of the rash. Symptoms include progressive tachypnea, dry cough, and dyspnea. Patients often have progressive hypoxia with diffuse bilateral infiltrates. In one of the rare times that radiographic pattern is diagnostic of the cause of pneumonia, nodular infiltrates can become calcified, especially in the early stages of disease.

Although not more frequent, varicella pneumonia in pregnancy is considerably more severe than in nonpregnant women. Varicella in people who are immunocompromised is also similar to that in people who are immunocompetent, except in the severity of the infection. These patients are at increased risk for dissemination throughout their organs, disseminated intravascular coagulation, persistent development of new skin lesions for weeks, more severe vesicles becoming large and hemorrhagic, and, of course, increased risk of pneumonia.

Diagnosis
Most cases of varicella infection (chicken pox and varicella zoster) are diagnosed clinically through the appearance of the typical vesicular rash at different stages. For varicella zoster, a painful, unilateral vesicular eruption usually occurs in a restricted dermatomal distribution. Further diagnostic testing is needed for an atypical rash or concern for disseminated disease in an immunocompromised host without typical cutaneous lesions. In these cases, PCR provides rapid and sensitive confirmation of VZV from clinical specimens obtained from skin lesions and body fluids, such as bronchoalveolar lavage. The bronchoalveolar lavage may be most helpful in patients with pneumonia-like symptoms in whom the diagnosis of varicella has not been confirmed. Performing direct immunofluorescent test on the scrapings from active vesicular lesions is also a rapid helpful test to diagnose varicella. Viral culture and serologic testing have not been found to be very helpful for diagnosis.

Treatment
Immediate treatment with intravenous acyclovir has been associated with improved outcomes. Steroids have also been used for treatment but are controversial. In an uncontrolled study of patients in the ICU already on antiviral and antibiotic therapy, those given steroids had shorter hospitalization (median difference, 10 days) and shorter ICU stay (median difference, 8 days) than historical controls.

Cytomegalovirus
Cytomegalovirus pneumonia is the most common viral pathogen in transplant recipients, acquired through either transfer of virus with the allograft or reactivation of the latent virus in the recipient, typically 1 to 3 months after transplantation. Incidence ranges from 1% to 9% of autologous HSCT recipients, 10% to 30% of allogeneic HSCT recipients, and 15% to 55% of lung transplant recipients. Mortality is high, at 31% to 100% in HSCT recipients and 54% to 100% in solid organ transplant recipients. Patients who have undergone HSCT usually present after engraftment but can also present much later in disease. In patients who have undergone lung transplant, cytomegalovirus pneumonia develops 15 to 60 days posttransplant. In cases of cytomegalovirus donor-positive/recipient-negative patients, the progression of the infection is rapid.

Cytomegalovirus is also among the most frequent viruses detected among patients in the ICU who are not immunosuppressed. This occurrence was first documented in 1996 when autopsies and lung biopsies performed on patients with acute respiratory failure and possible ventilator-associated pneumonia showed that 25 of 86 of patients who were not immunocompromised had histologic findings compatible with cytomegalovirus lung disease. Of course, viral detection does not necessarily correlate with viral disease, and this topic is still under much scrutiny. Regardless, subsequent studies have shown enough evidence that an interventional randomized trial using anticytomegalovirus drugs would be warranted.

Although patients can be asymptomatic, common presenting symptoms usually include fever, dyspnea, nonproductive cough, and hypoxia. The most common chest CT scan findings of cytomegalovirus pneumonia are multiple, small centrilobular nodules, patchy ground-glass opacities, and small bilateral/asymmetric foci of consolidation.

Cytomegalovirus pneumonia is established through the presence of viral inclusions on a cytologic or histologic specimen. Because the yield of these findings can be low, bronchoalveolar lavage fluid is often sent for rapid shell vial culture.

The primary treatment for acute cytomegalovirus pneumonia is ganciclovir (5 mg/kg intravenously every 12 hours for 14 to 21 days) followed by valganciclovir, 900 mg, orally daily for suppression. An alternative agent is foscarnet.
Although evidence is lacking, high-dose intravenous immunoglobulin has been used successfully in conjunction with ganciclovir to treat cytomegalovirus pneumonia.\textsuperscript{192}

**Bocavirus**

Bocavirus, a linear nonenveloped DNA virus, was newly discovered by Swedish scientists in 2005. Although the pathogenesis of the virus is unknown, bocavirus has been implicated in respiratory tract infections in adults, along with acute gastroenteritis in children and adults. Human bocavirus was detected through PCR in 4 of 273 respiratory samples of hospitalized adults.\textsuperscript{193} Another study performed in children showed that 36 of 1539 respiratory specimens were positive for bocavirus. Although described in immunocompromised individuals, the incidence is not known.\textsuperscript{194} In children, symptoms of bocavirus include cough, dyspnea, wheezing, rhinitis, fever, and diarrhea.\textsuperscript{195} In adults, symptoms are similar to atypical pneumonia or acute bronchitis. Although limited by availability, most diagnoses are PCR-based.\textsuperscript{196} Treatment is supportive care.

**SUMMARY**

Viruses cause a high percentage of community-acquired pneumonias. The advent of PCR and other molecular techniques has been associated with the detection of a higher prevalence of common respiratory viruses than previously suspected. Better diagnostics have shown new viral pathogens regularly in epidemics, immunocompromised patients, and occasionally children. Despite better diagnostics, treatment for all but influenza is still very limited.

**REFERENCES**

1. Heikkinen T, Jarvinen A. The common cold. Lancet 2003;361(9351):51–9.
2. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005;5(11):718–25.
3. Jennings GH. The clinical features of the pneumonias undergoing virus tests. Br Med J 1952;1(4750):123–9.
4. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008;63(1):42–8.
5. de Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in immunocompromised adults. Chest 2004;125(4):1343–51.
6. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med 2009;30(2):179–88.
7. Irwin RS, Rippe JM. Irwin and Rippe’s intensive care medicine. 6th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
8. Zhang Y, Hinojosa ME, Yoo N, et al. Viral and host strategies to take advantage of the innate immune response. Am J Respir Cell Mol Biol 2010;43(5):507–10.
9. Akaike T. Role of free radicals in viral pathogenesis and mutation. Rev Med Virol 2001;11(2):87–101.
10. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what’s new with respiratory viruses? Curr Opin Infect Dis 2002;15(4):355–67.
11. Fishman JA. Medical progress: infection in solid-organ transplant recipients. N Engl J Med 2007;357(25):2601–14.
12. Barton TD, Blumberg EA. Viral pneumonias other than cytomegalovirus in transplant recipients. Clin Chest Med 2005;26(4):707–20.
13. Dykewicz CA, Jaffe HW, Kaplan JE, et al. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2000;6(6A):659–64.
14. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006;19(3):571–82.
15. Sethi S. Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics 2002;57(3):56–61.
16. Shahangian A, Chow EK, Tian XL, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009;119(7):1910–20.
17. Bauer TT, Ewig S, Rodloff AC, et al. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 2006;43(6):748–56.
18. Hagau N, Slavcovic A, Gonganau DN, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care 2010;14(6):R203.
19. Johnstone J, Majumdar SR, Fox JD, et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008;134(6):1141–8.
20. Kim EA, Lee KS, Primack SL, et al. Viral pneumonias in adults: radiologic and pathologic findings. Radiographics 2002;(Spec No)22:S137–49.
21. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353(13):1363–73.
22. Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999;258(1):1–20.
23. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355(9206):827–35.
24. Gorbach SL, Bartlett JG, Blacklow NR. Infectious diseases. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2004.
25. Webster RG, Kendal AP, Gerhard W. Analysis of antigenic drift in recently isolated influenza A (H1N1) viruses using monoclonal antibody preparations. Virology 1979;96(1):258–64.
26. Webster RG, Wright SM, Castrucci MR, et al. Influenza—a model of an emerging virus disease. Intercontinental virology 1993;35(1–4):16–25.
27. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection—California, April–May, 2009. MMWR Morb Mortal Wkly Rep 2009;58(19):536–41.
28. Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection—Mexico, March–April 2009. MMWR Morb Mortal Wkly Rep 2009;58(17):467–70.
29. Khanna M, Kumar B, Gupta N, et al. Pandemic swine influenza virus (H1N1): a threatening evolution. Indian J Microbiol 2009;49(4):365–9.
30. Shrestha SS, Sverdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis 2011;52(Suppl 1):S75–82.
31. Viboud C, Miller M, Olson D, et al. Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. Version 59. PLoS Currents: Influenza. 2010.
32. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009;361(20):1935–44.
33. Centers for Disease Control and Prevention (CDC). Patients hospitalized with 2009 pandemic influenza A (H1N1)—New York City, May 2009. MMWR Morb Mortal Wkly Rep 2010;58(51):1436–40.
34. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303(15):1517–25.
35. Mancuso CE, Gabay MP, Steinke LM, et al. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother 2010;44(7–8):1240–9.
36. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically Ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011;183(9):1207–14.
37. Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011;183(9):1200–6.
38. Zuckerman AJ. Principles and practice of clinical virology. 6th edition. Chichester (United Kingdom): John Wiley & Sons; 2009.
39. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999;17(Suppl 1):S3–10.
40. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007;45(3):315–21.
41. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48(8):1003–32.
42. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med 2008;359(24):2579–85.
43. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1–62.
44. Belshé RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356(7):685–96.
45. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007;28(6):702–7.
46. Lehmann HC, Hartung HP, Kieseier BC, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–51.
47. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–51.
48. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA 2004;292(20):2478–81.
49. Glezen WP. Clinical practice. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1–62.
50. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1–62.
in the prophylaxis of influenza A infection. N Engl J Med 1982;307(10):580–4.
52. Palese P, Companis RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33(1):159–63.
53. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med 1997;337(13):874–80.
54. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106.
55. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45(12):1568–75.
56. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007;12(4):501–8.
57. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999;43(7):1616–20.
58. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006;194(Suppl 2):S119–26.
59. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364(9436):759–65.
60. Influenza A (H1N1) virus resistance to oseltamivir. World Health Organization Web site. Available at: http://www.who.int/csr/disease/influenza/h1n1_table/en/index.html. Accessed January 15, 2011.
61. Alymova IV, Taylor G, Takimoto T, et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother 2004;48(5):1495–502.
62. Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 2010;202(2):234–41.
63. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus infection in the United States. JAMA 2003;289(2):179–86.
patients with leukemia. Clin Infect Dis 1995;21(2):376–9.
81. Wald TG, Miller BA, Shult P, et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc 1995;43(2):170–4.
82. McCarthey AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999;24(12):1315–22.
83. Glezzen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543–6.
84. Glanville AR, Scott Al, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005;24(12):2114–9.
85. Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J Pediatr 1977;90(3):382–6.
86. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001;33(6):792–6.
87. Wendt CH, Fox JM, Hertz MI. Paramyxovirus infections. Pediatrics 2009;124(6):1694–701.
88. Ahluwalia G, Embree J, McNicol P, et al. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. J Clin Microbiol 1987;25(5):763–7.
89. Englund JA, Piedra PA, Jewell A, et al. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996;34(7):1649–53.
90. Puppe W, Weigl JA, Aron G, et al. Evaluation of a multiplex reverse transcriptase PCR ELISA for the detection of nine respiratory tract pathogens. J Clin Virol 2004;30(2):165–74.
91. Langley JM, Smith MB, LeBlanc JC, et al. Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis: a randomized controlled clinical trial [ISRCTN46561076]. BMC Pediatr 2005;5(1):7.
92. Patel H, Platt R, Lozano JM, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004;3:CD004878.
93. King VJ, Viswanathan M, Bordley WC, et al. Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. Arch Pediatr Adolesc Med 2004;158(2):127–37.
94. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 1994;22(4):566–72.
95. Guerguerian AM, Gauthier M, Lebel MH, et al. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160(3):829–34.
96. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325(1):24–9.
97. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25(7):751–5.
98. Ljungman P, Ribaud P, Eurich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003;31(6):481–6.
99. Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37(8):1655–8.
100. Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma-globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 1991;35(7):1469–73.
101. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124(6):1694–701.
102. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002;196(6):859–65.
103. Pacini DL, Collier AM, Henderson FW. Adenovirus infections and respiratory illnesses in children in group day care. J Infect Dis 1987;156(6):920–7.
104. Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1997;158(4):362–86.
105. Wen CC, Kuo YH, Jan JT, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem 2007;50(17):4087–95.
107. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003;13(3):155–71.

108. Flomenberg P, Babbitt J, Drobskyi WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994;169(4):775–81.

109. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006;43(3):331–9.

110. Centers for Disease Control and Prevention. Two cases of adenovirus-related illness in previously healthy young adults—Illinois, 2000. MMWR Morb Mortal Wkly Rep 2001;50(26):553–5.

111. Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008;26(23):2890–8.

112. De Clercq E. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus infections. Rev Med Virol 1999;9(1):9–47.

113. Doan ML, Mallory GB, Kaplan SL, et al. Spread of adenovirus to geographically dispersed military installations, 2007. Emerg Infect Dis 2010;16(5):769–75.

114. Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008;26(23):2890–8.

115. Heim A, Ebnret C, Harste G, et al. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003;70(2):228–39.

116. De Clercq E. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus infections. Rev Med Virol 1999;9(1):9–47.

117. Turner RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 1999;281(19):1797–804.

118. Hendley JO. The host response, not the virus, causes the symptoms of the common cold. Clin Infect Dis 1998;26(4):847–8.

119. Hendley JO. The host response, not the virus, causes the symptoms of the common cold. Clin Infect Dis 1998;26(4):847–8.

120. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7(6):719–24.

121. Esper F, Martineo RA, Boucher D, et al. A 1-year experience with human metapneumovirus in...
children aged <5 years. J Infect Dis 2004;189(8):1388–96.
138. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350(5):443–50.
139. Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005;192(6):1061–5.
140. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006;144(5):344–9.
141. Falsey AR, Erdman D, Anderson LJ, et al. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003;187(5):785–90.
142. Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003;60(1):51–9.
143. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006;50(2):774–7.
144. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (based on data as of the 31 December 2003). World Health Organization Web site. Available at: http://www.who.int/csr/sars/country/table2004_04_21/en/index.html. Accessed January 15, 2011.
145. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1977–85.
146. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1953–66.
147. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004;141(9):662–73.
148. Liang G, Chen Q, Xu J, et al. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis 2004;10(10):1774–81.
149. Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005;11(12):1860–5.
150. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003;361(9371):1761–6.
151. Snider MT, Campbell DB, Kofke WA, et al. Venovenous perfusion of adults and children with severe acute respiratory distress syndrome. The Pennsylvania State University experience from 1982–1987. ASAIO Trans 1988;34(4):1014–20.
152. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348(20):1995–2005.
153. Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005;191(9):1472–7.
154. Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004;38(10):1420–7.
155. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003;58(8):686–9.
156. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361(9371):1767–72.
157. Bitar R, Weiser WJ, Avendano M, et al. Chest radiographic manifestations of severe acute respiratory syndrome in health care workers: the Toronto experience. AJR Am J Roentgenol 2004;182(1):45–8.
158. Muller NL, Ooi GC, Khong PL, et al. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol 2003;181(1):3–8.
159. Tang P, Louie M, Richardson SE, et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ 2004;170(1):47–54.
160. Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004;189(7):1158–63.
161. Chan KH, Cheng VC, Woo PC, et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol 2005;12(11):1317–21.
162. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3(9):1525–31.
163. Groneberg DA, Pouton SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005;5(3):147–55.
164. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290(24):3222–8.
165. Wong VW, Dai D, Wu AK, et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9(3):199–201.
166. Enjuanes L, Dediego ML, Alvarez E, et al. Vaccines to prevent severe acute respiratory syndrome
coronavirus-induced disease. Virus Res 2008; 133(1):45–62.

167. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004;101(8):2536–41.

168. Bian C, Zhang X, Cai X, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology 2009;383(1):39–46.

169. Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008;181(9): 6337–48.

170. Guess HA, Broughton DD, Melton LJ 3rd, et al. Population-based studies of varicella complications. Pediatrics 1986;78(4 Pt 2):723–7.

171. Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995–2005. J Infect Dis 2008;197:S94–100.

172. Feldman S. Varicella-zoster virus pneumonia. Chest 1994;106(1):S22–7.

173. Knyvett AF. Is smoking a risk factor for pneumonia in adults with chickenpox. Br Med J (Clin Res Ed) 1987;295(6590):122.

174. Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J 2003;21(5):886–91.

175. Esmonde TF, Herdman G, Anderson G. Chickenpox pneumonia: an association with pregnancy. Thorax 1989;44(10):812–5.

176. Straus SE, Ostrove JM, Inhausgpe G, et al. Varicella-zoster virus-infections - biology, natural-history, treatment, and prevention. Ann Intern Med 1988;108(2):221–37.

177. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005;352(5):450–8.

178. Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 2003;16(3):243–58.

179. Heiningen U, Seward JF. Varicella. Lancet 2006; 368(9544):1365–76.

180. Schlossberg D, Littman M. Varicella pneumonia. Arch Intern Med 1988;148(7):1630–2.

181. Floudas CS, Kanakis MA, Andreopoulos A, et al. Nodular lung calcifications following varicella zoster virus pneumonia. QJM 2008;101(2):159.

182. Balfour HH. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med 1988;85(2A): 68–73.

183. Schmutzhard J, Riedel HM, Wirgart BZ, et al. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004;29(2): 120–6.

184. Dahl H, Marcoccia J, Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol 1997;35(2):347–9.

185. Haake DA, Zakowski PC, Haake DL, et al. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults - retrospective controlled-study and review. Rev Infect Dis 1990;12(5): 788–98.

186. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998; 114(2):426–31.

187. Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005; 26(4):691–705.

188. Papazian L, Fraisse A, Garbe L, et al. Cytomegalo-virus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996;84(2):280–7.

189. Chiche L, Forel JM, Papazian L. The role of viruses in nosocomial pneumonia. Curr Opin Infect Dis 2011;24(2):152–6.

190. Kotloff RM, Ahyia VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170(1):22–48.

191. Harbison MA, De Girolami PC, Jenkins RL, et al. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988;46(1):82–8.

192. D’Alessandro AM, Pirsch JD, Stratta RJ, et al. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients. Transplant Proc 1989;21(3):3560–1.

193. Chow BD, Huang YT, Esper FP. Evidence of human bocavirus circulating in children and adults, Cleveland, Ohio. J Clin Virol 2008;43(3):302–6.

194. Kupfer B, Vehreschild J, Cornely O, et al. Severe pneumonia and human bocavirus in adult. Emerg Infect Dis 2006;12(10):1614–6.

195. Dina J, Vabret A, Gouarin S, et al. Detection of human bocavirus in hospitalised children. J Paediatr Child Health 2009;45(5):149–53.

196. Choi JH, Chung YS, Kim KS, et al. Development of real-time PCR assays for detection and quantification of human bocavirus. J Clin Virol 2008;42(3): 249–53.